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Determination of iron-overload in thalassemia by hepatic MRI and ferritin
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Accumulation of iron in thalassemia causes organ damage and reduces patient survival
due to heart lesions in the second decade of life. Iron deposits are monitored by direct
(biopsy) and indirect methods (ferritin) with sequential data being better than isolated
measurements. This paper compares two indirect measurements of iron overload; a
single hepatic iron concentration (HIC) by magnetic resonance and mean ferritin
levels over four years. A retrospective study of 25 patients from the Centro Regional
de Hemoterapia in Ribeirão Preto, Brazil was carried out. High HIC (above 7 mg per
gram of dry weight) was found in 20 patients and high mean serum ferritin (above
2500 µg/L) in 10 patients. Stratification into three levels (low, moderate and high) of
iron overload gave similar results in both tests. Many other factors influence de degree
of iron overload in thalassemia. No correlation was found using a non-parametric
statistical test between HIC and mean serum ferritin. Both methods provide better
planning of chelation therapy. Rev. Bras. Hematol. Hemoter. 2008;30(6):449-452.
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Introduction
The accumulation of iron in thalassemia causes
organic injuries and a reduction in survival and must be
treated with iron chelators such as deferoxamine. The
success of treatment depends essentially on patient
adherence and can be evaluated by determining iron loading
by direct or indirect methods. The accumulation of
transfusional and absorbed iron in thalassemia is
approximately 7 to 14 grams per year. The measurement of
iron is important for the prognosis (risk of organic and
associated injuries) and monitoring chelation.1,2
Ferritin is the principal iron storage protein, found in
the liver, spleen, bone marrow, and to a small extent in the
blood (serum ferritin - SF).3 In the majority of clinical centers,
the standard method of evaluating the total amount of body
iron is measurement of the SF concentration in the blood.4
However, the correlation between SF and body iron is not
sufficiently precise to be of high prognostic value, especially
when associated with inflammation or tissue damage.
Moreover, alterations in the relationship between blood serum
ferritin concentration and body iron content by chelation
and vitamin C treatment are complex. For example, the
relationship between serum ferritin and body iron appears to
be singular for different hematologic conditions.5 SF has been
the primary clinical measure of iron stores in thalassemic
patients undergoing transfusions. It is non-invasive, widely
available, inexpensive, but has not been systematically
compared to validated quantitative measurements of liver
iron using techniques such as MRI.6
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The liver is the main iron storage organ in the body,
containing approximately 70% of the total content of the body.
Liver iron can be assessed by needle biopsy or, more recently,
by noninvasive magnetic resonance imaging (MRI). As liver
iron correlates with total body iron, an alternative to evaluating
body iron overload is the measurement of liver iron
concentration (LIC). Thus, liver iron concentration (LIC) gives
a measure of parenchymal and macrophage iron stored in
Kupfer cells. Direct methods, such as hepatic biopsy and
susceptometry, are not influenced by other factors, but are
difficult to achieve, due to their invasiveness and high cost
and because the equipment is generally unavailable.6
Amongst the indirect methods, measurement of the
amount of liver iron by MRI is the best, because of its
advantage of not being invasive and also because it allows
an anatomical view of iron overload in the liver. This method
enables measurement of iron in milligrams per gram of tissue,
and estimates of the risk of organic diseases.7 SF has been
compared with liver iron in transfused thalassemia major
patients and demonstrated a good correlation, but a wide
prediction range reduces its clinical utility. Despite the
limitations of isolated SF and LIC comparisons, SF followed
over time, as a trend or as a mean, has been a reasonable
predictor of clinical outcome.8
The clinical consequences of iron overload are varied
and reflect the key sites of iron storage. In the liver, the
formation of collagen and portal fibrosis have been shown to
occur after about two years of transfusion therapy. Iron
accumulation in the heart is the leading cause of death in
patients with thalassemia major. Endocrine glands are also
affected. Patient compliance with treatment regimens and
effective chelation therapy are thought to be the main factors
associated with improved survival.4,7 Patients with serum
ferritin persistently above 2500 µg/L have a greater risk of
cardiac injury, but interference of other biological factors
exists, turning this into an inexact evaluation4 with some
authors preferring a value of 1500 µg/L.8 Measurements of
LIC above 1.6 mg/g of dry weight (mg/gdw) are considered
high, there is a small risk of complications when under 7 mg/
gdw, between 7 and 15 mg/gdw are intermediate values and
patients with above 15 mg/gdw have a risk of serious injury,
including fibrosis and cirrhosis of the liver, and cardiac
death.3,7 Infection by Hepatitis C Virus (HCV) with
inflammation does not affect the MRI measurements, but may
affect ferritin.8
As the accumulation of iron in the myocardium seems
to be associated with arrhythmias and organ insufficiency,
the measurement of cardiac iron is also important, but is
calculated using a different technique.9
The main objective of this paper is to quantify liver iron
concentration (LIC) by magnetic resonance in multitransfused
thalassemia patients chelated with deferoxamine and compa-
re this to mean ferritin values over a four-year period as well
as classify patients for risk of illness and death.
Patients and Method
A retrospective study in a group of thalassemia major
and intermediate patients, followed at the Centro Regional
de Hematologia e Hemoterapia (Regional Blood Center) of
Ribeirao Preto Hospital and Clinics-HCRP, (Hospital das Clí-
nicas of the Medicine School in Ribeirão Preto) was
performed, in which 43 magnetic resonance investigations
were carried out for the quantification of LIC. Evaluations
were carried out in the Radiology Department of HCRP and
in the Physics and Mathematics Department, University of
Philosophy, Sciences and Languages of Ribeirão Preto,
University of São Paulo, campus of Ribeirão Preto, Brazil. To
evaluate liver iron overload, MR images were acquired using
two SE and two GRE sequences on a 1.5-T whole body scanner
(Siemens Magneton Vision Plus). LIC values from relaxometry
(R2) using SSE sequences were computed according to the
protocol developed by Clark and St. Pierre,10,11 who validated
their protocol of quantifying iron overload from R2 using
more than 100 biopsies.
Twenty-five patients including 11 women with an
average age of 21 ± 7 years old (range: 6 to 39) were evaluated.
They had been multitransfused since infancy, were under
chelation with deferoxamine with good adherence to treatment
and had a yearly blood consumption below 200 mL per
kilogram. The LIC was quantified, as described, in milligrams
per gram of dry weight (mg/gdw) of liver with normal values
being under 1.6 mg/gdw.10,11
The serum ferritin was assessed by chemoluminescence
and an average of 15 measurements per patient were performed
over a four-year period. Normal values are 300 µg/L for men
and 150 µg/L for women.
The data was analyzed using the Spearman correlation
by the Instat program version 3.01 (GraphPad Software, Inc.)
with values under 0.05 being considered significant.
Results
The average serum ferritin level was 2,337 ± 1,012 µg/L
(range: 481-7595). In 4/25 patients mean SF measurements
were under 1500 µg/L (low risk of complications), in 11/25
patients between 1500 µg/L and 2500 µg/L (intermediate risk),
and in 10/25 above 2500 µg/L (high risk). An average LIC of
14.16 ± 8.09 (range: 3.3-36.3) mg/gdw was found. In 5/25 patients
values were under 7 mg/gdw (low risk of complications), in
11/25 between 7 and 15 mg/gdw (intermediate risk), and in 9/
25 the concentration was above 15 mg/gdw (high risk).
Injuries from iron accumulation were found in 19/25
patients and were mainly heart related (arrhythmia or
insufficiency) in three, diabetes mellitus in one, growth
retardation in four and hypogonadism in eleven patients.
In 12/25 there were antibodies against Hepatitis C Virus (ab
anti-HCV). In only 11/25 patients there was concordance
between SF and LIC for risk of organ disease.
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but thanks to aggressive chelation, this rate has dropped
to between 50 to 67% and, in particular, increased the
survival of women, even though clearance of myocardial
iron is slower than hepatic deposits. Currently, 5% of the
patients present cardiac injury, such as arrhythmias or organ
insufficiency.13-16
The results presented here are of a group of young
patients, transfused since infancy and with good adherence
to chelation using deferoxamine. The majority already have
endocrine gland lesions due to iron accumulation. There was
concordance of risk as estimated by LIC and mean ferritin
levels in only 11 individuals, but overall results were very
similar. High risk was identified in 10/25 using serial ferritin
measurements and in 9/25 patients by LIC. These patients
need aggressive chelation therapy immediately. Thus the
estimate of the accumulation of liver, and thus body, iron by
magnetic resonance did not identify more at-risk patients
than the mean SF levels, but only one measurement was
required. LIC needs to be performed periodically, for example,
once a year, and at shorter intervals for intensively cheated
patients. SF must be measured at least 3 times a year.
Measurement of liver iron allows real quantification of iron
accumulation, the effectiveness of chelation and enables
changes in strategy17 at a glance. This requires much time
with SF. There are many other factors that influence iron
loading and organ disease in thalassemia and treatment must
be individualized. Perhaps the best strategy would be to use
both techniques, mean SF and LIC by MRI, frequently. But
MRI is not as accessible as SF. Machines are expensive and
busy in public hospitals. We suggest that, for thalassemia
patients undertaking blood transfusion, the mean SF should
be kept under 1500 mg/L by chelation if possible and organ
function should be monitored closely. A LIC evaluation
performed once per year is an additional tool to monitor iron
accumulation however prognosis must not be based on an
isolated measurement.
Resumo
O acúmulo de ferro na talassemia causa lesões orgânicas e reduz a
sobrevida do paciente por lesão cardíaca na segunda década da
vida, e tem sido avaliado por medidas diretas (biópsia) e indiretas
(ferritina). As medidas isoladas carecem de valor, sendo preferidas
as sequenciais. Este trabalho pretende comparar medidas indiretas
de sobrecarga de ferro, uma medida da concentração de ferro
hepático por ressonância magnética, e a ferritina sérica média dos
últimos quatro anos. Trata-se de estudo retrospectivo de 25 pacien-
tes do Centro Regional de Hemoterapia, em Ribeirão Preto, Brasil.
Encontrou-se em vinte pacientes ferro hepático acima de 7 mg/g
peso seco e ferritina média elevada acima de 2.500 ug/l em dez.
Estratificação em três níveis de sobrecarga (leve, moderada e gra-
ve) produziu resultados semelhantes em ambos os testes. Vários
outros fatores influenciam o grau de sobrecarga de ferro na
talassemia. Não houve correlação significativa com aplicação de
testes não-paramétricos. Ambos os métodos usados concomitan-
No correlation was found between mean ferritin and
LIC using the Spearman test, (r = 0.2655, 95% CI - 0.1570 to
0.6059, p = 0.1995 - not significant). Table 1 shows risk
classification and the results of the LIC and mean ferritin
levels of the patients.
Discussion
The validation of a method of iron measurement in
multitransfused patients is essential to optimize therapeutic
chelation, controlling iron loading and avoiding chelator
toxicity. Traditionally it is achieved using serum ferritin with
known limitations.12 Magnetic resonance imaging seems to
be a better method. It is less invasive than liver biopsy and
is not affected by interference from fibrosis.8 Cardiac injury
was responsible for death of 70% of the patients in the past
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temente levarão a um melhor planejamento da terapia quelante.
Rev. Bras. Hematol. Hemoter. 2008;30(6):449-452.
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sonância magnética; ferritina; quelação.
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